1. Abemaciclib for treating patients with HR+/HER2- metastatic breast cancer: a real-world study in France, Italy and Spain.
- Author
-
Blancas I, Grosjean J, Pedersini R, Buzzoni C, Sleilaty G, Molero A, Tamma A, Chouaki N, Atienza M, Emde A, Siddi S, Sanchez Bayona R, Del Mastro L, and Fakhouri W
- Subjects
- Humans, Female, Middle Aged, Spain epidemiology, Aged, France epidemiology, Adult, Italy epidemiology, Receptors, Progesterone metabolism, Receptors, Estrogen metabolism, Aged, 80 and over, Progression-Free Survival, Retrospective Studies, Neoplasm Metastasis, Breast Neoplasms drug therapy, Breast Neoplasms pathology, Breast Neoplasms mortality, Benzimidazoles therapeutic use, Aminopyridines therapeutic use, Receptor, ErbB-2 metabolism
- Abstract
Aim: This real-world study aimed to describe patient and clinical characteristics, treatment patterns and outcomes for patients with HR+/HER2- metastatic breast cancer receiving abemaciclib in France, Italy and Spain. Materials & methods: A multicenter chart review was conducted for adult females with HR+/HER2- advanced/metastatic breast cancer who received abemaciclib in routine care. Real-world progression-free survival (rwPFS) was estimated via Kaplan-Meier curves. Results: This study included 151, 173 and 175 patients from France, Italy and Spain, respectively. Abemaciclib was mostly prescribed as first-line therapy concomitantly with hormone therapy. Median rwPFS was >20 months and the 1-year rwPFS rate was >70%. Conclusion: Effectiveness was similar across the three countries and aligns with pivotal studies.
- Published
- 2024
- Full Text
- View/download PDF